FOLD•benzinga•
Amicus Therapeutics 2025 Guidance: Expects Total Revenue Growth Of 17%-24%, Gross Margin In Mid 80% And GAAP Net Income Positive In Second-Half
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 19, 2025 by benzinga